Is HRT safe for women with fibroids or endometriosis?

Whether HRT is appropriate for individuals with fibroids or endometriosis depends on many personal health factors that cannot be assessed through website content alone. A prescriber should evaluate each situation based on the type, size, and activity of the condition, current symptom burden, and overall health history before recommending any hormonal regimen.

How HRT may affect fibroids

Fibroids are benign uterine growths that are sensitive to estrogen. According to current NAMS guidelines, most postmenopausal women with fibroids do not experience clinically significant fibroid growth on standard HRT doses, and menopausal symptoms such as vasomotor episodes often improve substantially after natural estrogen decline. Per published clinical guidelines, lower estrogen doses and transdermal delivery routes are generally associated with more stable systemic hormone levels compared to oral preparations, which may be relevant for patients with estrogen-sensitive conditions.

• Lower estrogen doses are associated with reduced stimulation of estrogen-sensitive tissue, per published clinical guidelines.
• Transdermal estrogen (patch, gel, spray) achieves more consistent serum levels and avoids first-pass hepatic metabolism, according to the Endocrine Society.
• Adding progestogen protects the uterine lining and helps maintain endometrial stability, per FDA-approved prescribing information for combined HRT products.

How HRT may affect endometriosis

Endometriosis tissue is hormonally responsive. According to current NAMS guidelines, endometriosis lesions typically become quiescent after natural menopause, though estrogen therapy may occasionally reactivate residual tissue in some individuals. Per published clinical guidelines, continuous combined HRT — estrogen plus daily progestogen — is generally preferred over estrogen-only regimens in women with a history of endometriosis, as the progestogen component suppresses endometrial and ectopic endometrial activity.

• Continuous combined HRT is preferred because progestogen helps keep endometriosis tissue inactive, per published clinical guidelines.
• Estrogen-only therapy is generally avoided in women with a uterus or a history of active endometriosis, according to ACOG.
• Low, steady estrogen levels are associated with a reduced likelihood of symptom recurrence, per the Endocrine Society.

When closer monitoring is warranted

According to current NAMS guidelines, women with very large fibroids causing compressive symptoms, a documented history of rapid fibroid growth, or severe endometriosis that previously required surgical intervention may require more frequent monitoring if HRT is initiated. Per published clinical guidelines, lower starting doses and regular symptom review are recommended in these higher-complexity cases. A prescriber can weigh individual risk factors and adjust the regimen accordingly.

A note on compounded preparations

Some individuals with fibroids or endometriosis may be offered compounded hormone formulations allowing dose adjustments. Compounded medications are not FDA-approved. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved medications should be considered first when commercially available options meet patient needs.

Discussing options with a prescriber

Whether HRT is appropriate depends on individual health factors. A prescriber should determine the best approach based on a patient's complete medical history, including the nature and severity of fibroids or endometriosis, prior treatments, and current symptom profile.